IN THE NEWS
Despite how far we have come, there is still ample room to grow
Meg LaTorre-Snyder, Editor
Nov. 2, 2016
Biosimilars have come a long way since their initial entry in the U.S. on March 6, 2015. However, with a number of unanswered questions (such as pricing, availability, and interchangeability) and a lack of understanding in the marketplace, biosimilars still have so much opportunity to grow in prominence in the U.S.
Please click on the link to read the rest of the story …